Table 1.
Characteristics and outcomes of included patients
| Characteristic | Responder (n=9) | Non-responder (n=10) | p |
|---|---|---|---|
| Age, years; median (IQR) | 68 (62–73) | 66 (59–69) | 0.88 |
| Male sex (%) | 8 (89) | 6 (60) | 0.36 |
| Clinical nodal status1 (%) | 1 | ||
| 0 | 8 (89) | 8 (80) | |
| 1 | 1 (11) | 2 (20) | |
| Neoadjuvant chemotherapy2 | 0.962 | ||
| GC (%) | 8 (89) | 10 (100) | |
| Cycles, median (range) | 4 (2–6) | 4 (2–4) | |
| MVAC (%) | 1 (11) | 0 | |
| Cycles, median (range) | 4 | – | |
| Pathological stage (%) | |||
| Tumor stage | <0.05 | ||
| T0 | 7 (78) | 0 | |
| Ta | 1 (11) | 0 | |
| T1 | 1 (11) | 0 | |
| T2 | 0 | 5 (50) | |
| T3 | 0 | 3 (30) | |
| T4 | 0 | 2 (20) | |
| Nodal stage | 0.20 | ||
| N0 | 9 (100) | 7 (70) | |
| N1 | 0 | 2 (20) | |
| N2 | 0 | 1 (10) | |
| Outcomes (%) | |||
| Distant recurrence | 3 (33) | 6 (60) | 0.48 |
Aside from the expected difference in pathological stage, no statistically significant differences were noted between the two groups.
1
Nodal status was determined on pretreatment computed tomography imaging completed prior to neoadjuvant chemotherapy.
2
Statistical testing completed on proportion of patients who received each chemotherapy regimen.
GC: gemcitabine-cisplatin; IQR: interquartile range; MVAC: methotrexatevinblastine-doxorubicin-cisplatin.